Ignite Creation Date:
2024-05-06 @ 3:08 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02219711
Status:
COMPLETED
Last Update Posted:
2023-03-06
First Post:
2014-08-14
Brief Title:
Phase 11b Study of MGCD516 in Patients With Advanced Cancer
Sponsor:
Mirati Therapeutics Inc
Organization:
Mirati Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Cancer |
Keywords:
| Name | View |
|---|---|
| MGCD516 | View |
| MET | View |
| AXL | View |
| RET | View |
| TRK | View |
| NTRK | View |
| DDR2 | View |
| KDR | View |
| VEGFR | View |
| PDGFRA | View |
| KIT | View |
| Tyrosine kinase inhibitor | View |
| NSCLC | View |
| Non-small cell lung cancer | View |
| Head and neck cancer | View |
| Renal cell carcinoma | View |
| Prostate cancer | View |
| Phase 1 | View |
| CBL | View |
| Sitravatinib | View |